Clinical trials: Reduced Ejection Fraction Heart Failure
Heart Failure, Heart Failure With Preserved Ejection Fraction
Balance, Aerobic Capacity, Mobility and Strength in Patients Hospitalized for Heart Failure (BAMS-HF) Program
This is a pilot randomized trial of the BAMS-HF (Balance, Aerobic capacity, Mobility and Strength in patients hospitalized for Heart Failure) Program versus usual care.
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure, Systolic, Heart Failure, Diastolic
- Trial name
- BAMS-HF (NCT04281849)
- Testing
- BAMS-HF Program
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- VA Eastern Colorado Health Care System
Heart Failure
Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart Failure
We hypothesize that Dapagliflozin could improve the diuretic response in diabetic patients with acute decompensated heart failure owing to its diuretic effect in addition to improvement of blood glucose level without remarkable…
- Trial name
- NCT04385589
- Testing
- Dapagliflozin, insulin
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Assiut University
Type2diabetes, Heart Failure With Reduced Ejection Fraction
Ketones, SGLT2, HFrEF
The study team will examine the effects of elevated plasma ketone levels following initiation of SGLT2 inhibitor therapy in high-risk type 2 diabetes mellitus (T2DM) individuals with heart failure (HF) with reduced ejection…
- Trial name
- NCT06229678
- Testing
- Empagliflozin 25 MG Oral Tablet, Acipimox 250 Mg Oral Capsule
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Heart Failure With Reduced Ejection Fraction
A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure
The purpose of this study is assess the effect of danicamtiv, as an inducer on the drug levels of midazolam in participants with heart failure with reduced ejection fraction (HFrEF).
- Trial name
- NCT05952089
- Testing
- Danicamtiv, Midazolam
- Where
- 5 sites in United States
- Volunteers
- 13 people
- Sponsor
- Bristol-Myers Squibb
Side-Effect, Heart Failure
pErsonalised Nocebo Assessment of Beta-blockEr Symptoms in Heart Failure
Beta-blocker tablets are an effective treatment for heart failure that make people live longer and reduce the need to be admitted to hospital.
- Trial name
- ENABLE-HF (NCT07029906)
- Testing
- Bisoprolol 2.5 mg
- Where
- United Kingdom
- Volunteers
- 150 people
- Sponsor
- Imperial College London
HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction
Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension
This is a Phase 2a, open-label, multiple-dose study to assess the safety, tolerability, and efficacy of JK07 in participants 18 to 85 years of age with diagnosed HF and cpcPH.
- Conditions
- HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Group 2 Pulmonary Hypertension
- Trial name
- RENEU-PH (NCT07221513)
- Testing
- JK07
- Where
- United States
- Sponsor
- Salubris Biotherapeutics Inc
Heart Failure With Reduced Ejection Fraction, Heart Rhythm Disorder
Withdrawal of Treatment for Heart Failure Patients With Recovery From Tachycardia-induced Cardiomyopathy
New onset heart failure (HF) is observed in up to 25% of patients with incident atrial fibrillation or flutter (AF). Current guidelines suggest that both conditions (AF \& HF) be addressed with guideline directed medical therapy…
- Trial name
- WEAN-HF (NCT06128980)
- Testing
- GDMT
- Where
- Denmark
- Volunteers
- 348 people
- Sponsor
- Herlev and Gentofte Hospital
Heart Failure With Reduced Ejection Fraction, Chronic Heart Failure
Vericiguat and Exercise Hemodynamics in Patients With HFrEF
Heart failure with reduced ejection fraction (HFrEF) is associated with impaired exercise capacity and abnormal exercise hemodynamics despite contemporary guideline-directed medical therapy (GDMT).
- Trial name
- EVERHETT-HF (NCT07697365)
- Testing
- Vericiguat, Guideline-directed medical therapy (GDMT) for heart failure
- Where
- Greece
- Volunteers
- 40 people
- Sponsor
- Argyrios Ntalianis
Heart Failure
This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms
The primary objective of the study is to evaluate the effect of empagliflozin 10 mg versus placebo on exercise ability using the 6 minute walk test in patients with chronic HF with reduced ejection fraction (LVEF ≤ 40%) Secondary…
- Trial name
- NCT03448419
- Testing
- Empagliflozin
- Where
- 109 sites in United States, Australia and 9 more
- Volunteers
- 312 people
- Sponsor
- Boehringer Ingelheim
Heart Failure, Ischemic Heart Failure
Endocardial Delivery for Myocardial Regeneration Using Allogeneic iPSC-derived Cardiomyocyte Spheroids for HF With Systolic Dysfunction (EMERALD Study)
The purpose of this clinical study is to evaluate the safety and efficacy of endocardial delivery of HS-001 CS into severe heart failure patients with reduced ejection fraction for 26 weeks after transplantation.
- Conditions
- Heart Failure, Ischemic Heart Failure, Ischemic Heart Disease, Dilated Cardiomyopathy (DCM)
- Trial name
- EMERALD (NCT07347197)
- Testing
- HS-005
- Where
- 5 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Heartseed Inc.
Heart Failure With Reduced Ejection Fraction (HFrEF), Renal Impairment
AZD3427 Effects on Renal Perfusion in Heart Failure Patients With Reduced Ejection Fraction and Renal Impairment
The present study is designed to test the effect of AZD3427 on renal perfusion in participants with heart failure and reduced eGFR (30 to 90 mL/min/1.73m2).
- Trial name
- Re-PERFUSE (NCT06611423)
- Testing
- AZD3427, Dopamine, Radiolabelled ligand
- Where
- Sweden
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Heart Failure
Improving Goal Directed Medical Therapy for Device Clinic Patients With Reduced EF at UOHI: a QI Initiative (VIGILANT)
This is a quality improvement initiative with the goal of optimizing heart failure (HF) patients seen through the outpatient cardiac implantable electronic device clinic at the University of Ottawa Heart Institute (UOHI).
- Trial name
- VIGILANT (NCT05085249)
- Where
- Canada
- Volunteers
- 2,479 people, healthy volunteers welcome
- Sponsor
- Ottawa Heart Institute Research Corporation
Heart Failure With Reduced Ejection Fraction
First in Humans to Evaluate Collagen Patches With Stem Cells in Patients With Ischemic Left Ventricular Dysfunction
It´s a first open-label trial in humans to evaluate the safety and efficacy of epicardial delivery of collagen patches with adipose-derived stem cells in patients with ischemic heart disease and left ventricular dysfunction that…
- Trial name
- CARDIOMESH (NCT03746938)
- Testing
- VB-C01
- Where
- 2 sites in Spain
- Volunteers
- 10 people
- Sponsor
- Viscofan
HFpEF - Heart Failure With Preserved Ejection Fraction, HFmrEF
US Benchmarking Clinical Study
The goal of this observational study is to measure shear wave velocity (SWV) in patients with non-reduced left ventricular ejection fraction (LVEF) heart failure and left ventricular hypertrophy, with or without transthyretin…
- Conditions
- HFpEF - Heart Failure With Preserved Ejection Fraction, HFmrEF, ATTR-CM (Transthyretin Amyloid Cardiomyopathy), Left Ventricular Hypertrophy
- Trial name
- EMS-CT-1 (NCT07215715)
- Where
- 3 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- eMyosound SAS
Heart Failure
Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction
This was a randomized, double-blinded, placebo-controlled, multiple-dose study in subjects with stable heart failure (HF) with reduced ejection fraction (HFrEF).
- Trial name
- NCT02788747
- Testing
- 4 mg elamipretide, 40 mg elamipretide
- Where
- 15 sites in Italy, Netherlands and 1 more
- Volunteers
- 71 people
- Sponsor
- Stealth BioTherapeutics Inc.
Acute Heart Failure With Reduced Left Ventricular Ejection Fraction
Telemonitoring to Optimize Medication Titration for Heart Failure: a Feasibility Study
Problem: Aggressive titration of guideline-directed medical therapy is the cornerstone of heart failure management to reduce heart failure related hospitalization and mortality.
- Trial name
- TOM-HF (NCT07016815)
- Testing
- Wearable wrist heart rate and activity monitor, Bluetooth enabled body weight scale with bioimpedance analysis, Bluetooth enabled electronic blood pressure device
- Where
- 2 sites in Hong Kong
- Volunteers
- 80 people
- Sponsor
- Chinese University of Hong Kong
Heart Failure With Reduced Ejection Fraction, Hypotension
Midodrine in Heart Failure With Reduced Ejection Fraction With Hypotension
The evidence-based pharmacologic treatments available for patients with heart failure with reduced ejection fraction (HFrEF) has been established over the last few decades of cardiovascular research.
- Conditions
- Heart Failure With Reduced Ejection Fraction, Hypotension, LV Dysfunction
- Trial name
- MIDOH-HF-P (NCT06405555)
- Testing
- Midodrine Oral Tablet
- Where
- Canada
- Volunteers
- 56 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Heart Failure
A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs Heart Failure Patients With Reduced Ejection Fraction Using Secondary US Electronic Health Records Data
A non-interventional retrospective cohort study conducted to compare the naive sacubitril/valsartan Heart Failure with reduced Ejection Fraction (HFrEF) patient population to a matched naive ACEi/ARB HFrEF patient population.
- Trial name
- NCT05096143
- Testing
- Sacubitril/valsartan, ACEi/ARB
- Where
- United States
- Volunteers
- 42,269 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure，Congestive
Effects of Furosemide Plus Small HSS in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)
The investigators sought to evaluate the effectiveness of treatment with furosemide + HSS in terms of reduction of serum levels of some chosen markers of heart failure and the response in terms of these markers at a compensated…
- Trial name
- NCT04628325
- Testing
- Furosemide
- Where
- 2 sites in Italy
- Volunteers
- 136 people
- Sponsor
- University of Palermo
Heart Failure With Reduced Ejection Fraction HFrEF
Translational and Clinical Aspects of Metabolic, Anabolic and Endothelial Dysfunction in Heart Failure
In patients with HF cardiac output, metabolism and endothelial function will be studied during and after treatment with ghrelin infusion
- Trial name
- MetAnEnd-HF (NCT05277415)
- Testing
- Ghrelin
- Volunteers
- 31 people
- Sponsor
- Lars Lund